Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Vaxcyte (Nasdaq: PCVX) is a vaccine company dedicated to engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The company is developing broad-spectrum and novel conjugate and protein vaccines to prevent or treat common and deadly invasive bacterial infections. Vaxcyte's approach, leveraging its proprietary cell-free protein synthesis platform, XpressCF™, enables the design and production of complex vaccines that are difficult or impossible to produce with conventional methods. Their pipeline includes candidates targeting pneumococcal disease, Group A Strep, and periodontitis.
The headquarters serves as the central hub for Vaxcyte's research and development, clinical operations, corporate strategy, manufacturing process development, and administrative functions.
Modern laboratory and office spaces designed to foster collaboration and innovation. The facility houses Vaxcyte's proprietary XpressCF™ cell-free protein synthesis platform and related advanced R&D laboratories critical for vaccine design and production.
A mission-driven, innovative, and collaborative work environment. Employees are focused on scientific excellence and addressing significant unmet medical needs in infectious diseases. The culture emphasizes teamwork, problem-solving, and a fast-paced approach to vaccine development.
The San Carlos headquarters is pivotal for Vaxcyte's operations, housing its core scientific talent, leadership team, and the technological infrastructure underpinning its vaccine development programs. Its location in a biotech hub facilitates access to talent, resources, and industry collaborations.
Vaxcyte's global presence is primarily driven through its international clinical trial operations for its vaccine candidates, which often involve sites in multiple countries. The company also engages with global regulatory authorities and may collaborate with international research institutions and partners. Future global presence is anticipated to expand with the potential commercialization of its vaccines worldwide, involving global manufacturing, supply chain, and distribution networks.
825 Industrial Road, Suite 300
San Carlos
California
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Vaxcyte' leadership includes:
Vaxcyte has been backed by several prominent investors over the years, including:
Over the past year, Vaxcyte has made strategic additions to its executive team to bolster its technical operations and commercial readiness as its vaccine candidates progress through clinical development. No major C-level departures were publicly noted during this period.
Discover the tools Vaxcyte uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Vaxcyte's email format most likely follows a common corporate structure, typically using an employee's first initial and last name, followed by '@vaxcyte.com'. This is a standard pattern for many companies in the biotech industry.
flast@vaxcyte.com
Format
jdoe@vaxcyte.com
Example
85%
Success rate
Vaxcyte, Inc. (GlobeNewswire) • May 15, 2024
Vaxcyte announced the dosing of the first participants in its Phase 1/2 clinical study evaluating the safety, tolerability, and immunogenicity of VAX-31, its investigational 31-valent pneumococcal conjugate vaccine candidate, in healthy adults aged 18-64. This marks a significant step in advancing their next-generation PCV program aimed at broader protection against invasive pneumococcal disease....more
Vaxcyte, Inc. (GlobeNewswire) • October 30, 2023
Vaxcyte reported positive top-line results from its Phase 2 proof-of-concept study of VAX-24 in adults aged 65 and older. The study demonstrated that VAX-24 was well-tolerated and achieved robust immune responses, meeting its primary safety and immunogenicity objectives. These results support VAX-24's potential as a best-in-class, broader-coverage pneumococcal vaccine....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Vaxcyte, are just a search away.